Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.

Clinical neuropharmacology - 1 Jan 2000

Chong D J, Suchowersky O, Szumlanski C, Weinshilboum R M, Brant R, Campbell N R

Abstract excerpt

Patients with Parkinson's Disease (PD) have a variable response to tolcapone, a catechol-O-methyltransferase (COMT) inhibitor. In addition, a subset of patients develop severe diarrhea as a side effect. Two codominant alleles for the COMT gene exist, coding for low and high activity, resulting in low-, medium-, and high-activity genotypes. This study investigates the relationship between this variation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiparkinson Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catechol O-Methyltransferase

Share to Diarrhea

Share to Enzyme Inhibitors

Share to Levodopa

Share to Nitrophenols

Share to Parkinson Disease

Source

Identifiers

PMID: 10895397
DOI: 10.1097/00002826-200005000-00003

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.PMID 10895397Read ↗

Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?Semantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complicationsSemantic proximity Read ↗

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.Semantic proximity Read ↗

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.Semantic proximity Read ↗

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.Semantic proximity Read ↗

Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study.Semantic proximity Read ↗

High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease.Semantic proximity Read ↗

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.Semantic proximity Read ↗

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.